-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
- Cosmetic Ingredient
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
On the evening of September 1, AstraZenecom announced that its Phase III clinical trial of the COVID-19 vaccine AZD1222 would be expanded to the United States, the third new crown candidate to be tested in the United States.
the project, called D8110C00001, is funded by the U.S. Biomedical Advanced Research and Development Administration (BARDA) and the National Institute of Allergy and Infectious Diseases (NIAID).
now, AstraZeneta is recruiting nearly 30,000 adults aged 18 and over to conduct trials that include both healthy people and people with stable underlying conditions, as well as people from different ethnic groups and places.
, the volunteers also include people living with HIV and those at higher risk of new coronavirus infection.
the clinical trial, volunteers were divided into vaccine and control groups, each with two injections, four weeks apart.
said it plans to recruit more than 50,000 volunteers worldwide to take part in the trial.
addition to the 30,000 volunteers in the United States, the company will also launch volunteer recruitment in Latin America, Asia, Europe and Africa.
as part of its plan, AstraZeneta has reached supply agreements with Russia, South Korea, Japan, China, Latin America and Brazil to guarantee a global supply of 3 billion doses of vaccines.
June, AstraZenecom announced plans to produce 2 billion doses of the new crown vaccine, of which 400 million were distributed to the United States and the United Kingdom and 1 billion to low- and middle-income countries.
AZD1222 was jointly developed by AstraZeneta and Oxford University.
The results of previous trials published in The Lancet medical journal showed that the vaccine did not produce any serious side effects in 1,077 volunteers in early-stage clinical trials, meaning the vaccine was safe;
Lin Yiling Source: EY !-- content presentation ends -- !-- to determine whether the login ends.